葛根素注射液治疗脑梗死2500例  

Treatment of 2 500 Cases of Cerebral Infarction with Puerarin Injection

作　　者：邵自强[1] 焦劲松[1] 薛爽[1] 王国相[1] 

机构地区：[1]中日友好医院神经内科,北京100029

出　　处：《医药导报》2006年第6期517-518,共2页Herald of Medicine

摘　　要：目的研究葛根素注射液治疗脑梗死的临床效果。方法脑梗死患者共7 600例,除给予抗血小板聚集、脱水、抗感染以及控制血压、血糖、血脂等基础治疗外,对其中2 500例给予葛根素注射液500 mL.d-1,2 000例给予丹参注射液400 mL.d-1,2 000例给予三七总苷注射液450 mL.d-1,其余1 100例患者未加特殊治疗(对照组),疗程均为21 d。观察各组有效率、神经功能改善程度、病死率和梗死后脑出血(H I)发生率。结果葛根素组的有效率和神经功能改善程度高于丹参组和对照组,与三七总苷组相似;葛根素组患者病死率低于其他3组;葛根素组患者H I发生率高于对照组,低于三七总苷组,与丹参组相似。结论葛根素治疗能明显改善脑梗死患者神经功能,降低病死率。Objective To study the clinical effect of puerarin injection in the treatment of patients with cerebral infarction. Methods 7 600 inpatients with cerebral infarction serving as the subjects of the study were subjected to basic medical treatment including antiplatelet drugs, dehydration, antiinfectives, control of blood pressure, blood glucose, blood lipids, etc.. Of these, 2 500 patients were given each 500 mL of puerarin injection q. d. , 2 000 patients were given each 400 mL of red Sage root injection q. d. , another 2 000 patients were given each 450 mL of total notoginsenoside injection q. d.. All these drugs were administered by intravenous instillation. The remaining 1 100 patients serving as controls were not given additional special treatment. The course of treatment in all these patients lasted 21 days. The effective rate, extent of nervous function improvement, case fatality rate and incidence of postinfarction cerebral hemorrhage（CH） in patients of the different groups were compared. Results The overall effective rates in patients treated with puerarin, red sage root, total notoginsenoside and those serving as controls were 79.20% ,78.50% ,60. 15% and 36. 00%, respectively, the difference between the effective rates of the puerarin group and notoginsenoside group being significant （ P 〈 0.05 ） and that between the puerarin group and control group, highly significant（P 〈0.01 ）. The extent of nervous function improvement in patients of the puerarin group was significantly greater than that of red sage root group（P 〈 0.01 ） and control group （ P 〈 0.01 ） but similar to that of the notoginsenoside group（P 〉0.05）. The case fatality rate in patients of the puerarin group（ 1.40% ） was significantly lower than those of the notoginsenoside group（2.40% ,P 〈0.05）, red sage root group （3.60% ,P 〈0. 01 ） and control group （8.18% ,P 〈 0.01 ）. The incidence of CH in patients of the puerarin group （2.40%） was higher than that of the control group （1.10% ,P�

关 键 词：葛根素 丹参 三七总苷 脑梗死 

分 类 号：R282.71[医药卫生—中药学] R971[医药卫生—中医学]